UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/565,702	09/13/2006	Richard Martin	05-1128-A1	2568
63572 7590 08/07/2009 MCDONNELL BOEHNEN HULBERT @ BERGHOFF LLP 300 SOUTH WACKER DRIVE			EXAMINER	
			COLEMAN, BRENDA LIBBY	
SUITE 3100 CHICAGO, IL 60606			ART UNIT	PAPER NUMBER
			1624	
			MAIL DATE	DELIVERY MODE
			08/07/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
Office Action Occurrence	10/565,702	MARTIN ET AL.					
Office Action Summary	Examiner	Art Unit					
	Brenda L. Coleman	1624					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence add	dress				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be timil apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	J. lely filed the mailing date of this co (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on							
	_ · · · · · · · · · · · · · · · · · · ·						
3) Since this application is in condition for allowan	_						
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.					
Disposition of Claims							
4)⊠ Claim(s) <u>1-48</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) <u>1-48</u> are subject to restriction and/or e	8) Claim(s) 1-48 are subject to restriction and/or election requirement.						
Application Papers							
9) The specification is objected to by the Examiner							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Exa	aminer. Note the attached Office	Action or form PT	O-152.				
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:	priority under 35 U.S.C. § 119(a)	-(d) or (f).					
1. Certified copies of the priority documents	have been received.						
2. Certified copies of the priority documents		on No					
3. Copies of the certified copies of the prior	ty documents have been receive	ed in this National	Stage				
application from the International Bureau	(PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ite					
Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal P	атент друшсаноп					

DETAILED ACTION

Claims 1-48 are pending in the application.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-5 and 32-48, drawn to the compounds, compositions and method of use of the compounds of formula (I) where X-Y-Z together with the azepine ring form an azepino[4,5-b]indole ring.

Group II, claim(s) 1-13 and 46-48, drawn to the compounds, compositions and method of use of the compounds of formula (I) where X-Y-Z together with the azepine ring form an imidazo[4,5-d]azepine ring.

Group III, claim(s) 1-6, 14-23 and 32-48, drawn to the compounds, compositions and method of use of the compounds of formula (I) where X-Y-Z together with the azepine ring form an thieno[2,3-d]azepine ring.

Group IV, claim(s) 1-6, 14, 15, 24-31 and 46-48, drawn to the compounds, compositions and method of use of the compounds of formula (I) where X-Y-Z together with the azepine ring form an pyrroloo[2,3-d]azepine ring.

Group V, claim(s) 1-6, 14-17, 19-22, 32, 33 and 46-48, drawn to the compounds, compositions and method of use of the compounds of formula (I) where X-Y-Z together with the azepine ring form a ring other than those embraced by Groups I-IV above.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups I-IV are directed to structurally dissimilar compounds such that the variable core created by the

varying definitions of X, Y and Z in formula I do not belong to a recognized class of chemical compounds in the art, and references anticipating one invention, would not render obvious the others, for example azepino[4,5-b]indole is different from imidazo[4,5-d]azepine, pyrrolo[2,3-d]azepine, etc. Thus, separate searches in the literature as well as in the U.S. Patent Classification System would be required. Each group's compounds are made and used independently of each other and could support separate patents. The compounds differ significantly in chemical structures. One skilled in the art would not consider such diverse structures as functional equivalents of each other. The mere fact that there is a single similarity is not in itself a significant reason to render the whole embodiment obvious.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions anticipated by the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the

requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Tentative election of a single species within the elected group is further required.

If Group V is elected further restriction may be required.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda L. Coleman whose telephone number is 571-272-0665. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

Application/Control Number: 10/565,702 Page 5

Art Unit: 1624

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Brenda L. Coleman/ Primary Examiner, Art Unit 1624